INTS
$6.49
Pre-MarketAs of Mar 17, 8:00 PM UTC
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States.
Recent News
All You Need to Know About Intensity Therapeutics Inc. (INTS) Rating Upgrade to Buy
Intensity Therapeutics Inc. (INTS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BC-Most Active Stocks
EPWK Holdings Ltd. 1,389,291,372 0.1629
Intensity Therapeutics stock up nearly 400% on solid tumour data
The candidate is being investigated in a Phase III trial in sarcoma, with a breast cancer study planned.
Trending tickers: Apple, Amazon, Netflix, Reddit and Intensity Therapeutics
The latest investor updates on stocks that are trending on Friday
Is Cencora, Inc. (COR) Outperforming Other Medical Stocks This Year?
Here is how Cencora (COR) and Intensity Therapeutics Inc. (INTS) have performed compared to their sector so far this year.